Laurus Labs Limited Share Price & Analysis
₹1,445.5Updated 5 Jun 2026, 03:30 pm IST
LTP
₹1,445.5
—
Open
₹1,435
High
₹1,450.1
Low
₹1,428.4
Close
₹1,427.2
52W High
₹1,399
52W Low
₹609
Volume
1515K
Lot Size
850
Sector
Healthcare
Market Cap
₹75K Cr
Face Value
₹2
Large CapNIFTY 200NIFTY 500MIDCAP 100
Price Chart
Fundamentals
P/E
84
Sector P/E
48.9
P/B
14.72
EPS
₹15.62
ROE
18.2%
ROCE
17.7%
D/E Ratio
0.48
Div Yield
0.14%
Book Value
₹98.2
+
Strengths
- ✓Strong return on equity (ROE 18.2%)
- ✓Efficient capital deployment (ROCE 17.7%)
- ✓Low debt relative to equity (D/E 0.5x)
−
Concerns
- ✗Premium to sector peers (P/E 84x vs industry 48.9x)
- ✗High premium to book value (P/B 14.7x)
- ✗Trading near 52-week high (₹1,399)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LAURUSLABS · as of Mar 2026
Promoters27.62%
FII25.51%▼0.05
DII11.78%▼0.96
Public35.09%▲1.00
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 27.18% | 27.18% | 27.18% | 27.18% | 27.62% | 27.62% |
| FII | 25.39% | 25.98% | 25.67% | 26.08% | 25.56% | 25.51% |
| DII | 11.13% | 11.78% | 13.56% | 13.05% | 12.74% | 11.78% |
| Public | 36.30% | 35.07% | 33.59% | 33.69% | 34.09% | 35.09% |
Corporate Events
Interim Dividend - Rs 1.20 Per Share
Dividend7 May 2026
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend29 Apr 2026
Interim Dividend - Re 0.80 Per Sh
Dividend30 Oct 2025
Interim Dividend - Rs 0.80 Per Share
Dividend8 May 2025
Interim Dividend - Rs 0.40 Per Share
Dividend5 Nov 2024
Annual General Meeting
AGM3 Jul 2024
Interim Dividend - Re 0.40 Per Share
Dividend7 May 2024
Interim Dividend - Re 0.40 Per Share
Dividend1 Nov 2023
Annual General Meeting
AGM6 Jul 2023
Interim Dividend - Rs 1.20 Per Share
Dividend9 May 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.8K Cr ▲7.6% | ₹1.7K Cr ▲5.3% | ₹1.6K Cr ▼8.7% | ₹1.7K Cr ▲21.6% | ₹1.4K Cr ▲15.6% | ₹1.2K Cr ▲2.4% | ₹1.2K Cr ▼17.0% | ₹1.4K Cr |
| Op. Profit | ₹480 Cr ▲19.1% | ₹403 Cr ▲5.5% | ₹382 Cr ▼9.3% | ₹421 Cr ▲47.7% | ₹285 Cr ▲60.1% | ₹178 Cr ▲4.1% | ₹171 Cr ▼29.0% | ₹241 Cr |
| OPM | 27.0% ▲12.5% | 24.0% ▲0.0% | 24.0% ▲0.0% | 24.0% ▲20.0% | 20.0% ▲33.3% | 15.0% ▲7.1% | 14.0% ▼17.6% | 17.0% |
| Net Profit | ₹252 Cr ▲29.9% | ₹194 Cr ▲19.8% | ₹162 Cr ▼30.5% | ₹233 Cr ▲150.5% | ₹93 Cr ▲365.0% | ₹20 Cr ▲53.8% | ₹13 Cr ▼82.7% | ₹75 Cr |
| EPS (₹) | 4.66 ▲29.1% | 3.61 ▲19.5% | 3.02 ▼30.3% | 4.33 ▲153.2% | 1.71 ▲362.2% | 0.37 ▲60.9% | 0.23 ▼83.6% | 1.4 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6.8K Cr ▲22.7% | ₹5.6K Cr ▲10.2% | ₹5.0K Cr ▼16.6% | ₹6.0K Cr ▲22.4% | ₹4.9K Cr ▲2.5% | ₹4.8K Cr ▲70.0% | ₹2.8K Cr ▲23.6% | ₹2.3K Cr ▲11.5% | ₹2.1K Cr ▲7.9% | ₹1.9K Cr |
| Expenses | ₹5.0K Cr ▲11.9% | ₹4.5K Cr ▲5.6% | ₹4.3K Cr ▼4.2% | ₹4.4K Cr ▲26.7% | ₹3.5K Cr ▲7.7% | ₹3.3K Cr ▲44.0% | ₹2.3K Cr ▲17.1% | ₹1.9K Cr ▲17.8% | ₹1.6K Cr ▲9.7% | ₹1.5K Cr |
| Op. Profit | ₹1.8K Cr ▲68.5% | ₹1.1K Cr ▲35.4% | ₹779 Cr ▼51.1% | ₹1.6K Cr ▲11.8% | ₹1.4K Cr ▼8.2% | ₹1.6K Cr ▲174.7% | ₹565 Cr ▲58.3% | ₹357 Cr ▼13.8% | ₹414 Cr ▲1.5% | ₹408 Cr |
| OPM | 26.0% ▲36.8% | 19.0% ▲26.7% | 15.0% ▼42.3% | 26.0% ▼10.3% | 29.0% ▼9.4% | 32.0% ▲60.0% | 20.0% ▲25.0% | 16.0% ▼20.0% | 20.0% ▼4.8% | 21.0% |
| Other Income | ₹55 Cr ▼26.7% | ₹75 Cr ▲212.5% | ₹24 Cr ▲300.0% | ₹6 Cr ▼57.1% | ₹14 Cr ▼39.1% | ₹23 Cr ▲360.0% | ₹5 Cr ▼66.7% | ₹15 Cr ▼48.3% | ₹29 Cr ▼9.4% | ₹32 Cr |
| Interest | ₹171 Cr ▼20.8% | ₹216 Cr ▲18.0% | ₹183 Cr ▲10.9% | ₹165 Cr ▲61.8% | ₹102 Cr ▲50.0% | ₹68 Cr ▼24.4% | ₹90 Cr ▲2.3% | ₹88 Cr ▲10.0% | ₹80 Cr ▼20.0% | ₹100 Cr |
| Depreciation | ₹480 Cr ▲11.6% | ₹430 Cr ▲11.7% | ₹385 Cr ▲18.8% | ₹324 Cr ▲29.1% | ₹251 Cr ▲22.4% | ₹205 Cr ▲9.6% | ₹187 Cr ▲14.0% | ₹164 Cr ▲31.2% | ₹125 Cr ▲17.9% | ₹106 Cr |
| PBT | ₹1.2K Cr ▲144.2% | ₹484 Cr ▲105.1% | ₹236 Cr ▼78.7% | ₹1.1K Cr ▲2.3% | ₹1.1K Cr ▼16.7% | ₹1.3K Cr ▲342.5% | ₹294 Cr ▲145.0% | ₹120 Cr ▼49.4% | ₹237 Cr ▲1.3% | ₹234 Cr |
| Tax % | 25.0% ▼7.4% | 27.0% ▼6.9% | 29.0% ▲3.6% | 28.0% ▲21.7% | 23.0% ▼4.2% | 24.0% ▲84.6% | 13.0% ▼40.9% | 22.0% ▼24.1% | 29.0% ▲52.6% | 19.0% |
| Net Profit | ₹890 Cr ▲148.6% | ₹358 Cr ▲121.0% | ₹162 Cr ▼79.6% | ₹793 Cr ▼4.7% | ₹832 Cr ▼15.4% | ₹984 Cr ▲285.9% | ₹255 Cr ▲171.3% | ₹94 Cr ▼44.0% | ₹168 Cr ▼11.6% | ₹190 Cr |
| EPS (₹) | 16.46 ▲147.9% | 6.64 ▲122.8% | 2.98 ▼79.7% | 14.67 ▼4.7% | 15.4 ▼16.0% | 18.33 ▲284.3% | 4.77 ▲171.0% | 1.76 ▼44.3% | 3.16 ▼12.2% | 3.6 |
| Div Payout | 7.0% ▼61.1% | 18.0% ▼33.3% | 27.0% ▲92.9% | 14.0% ▲7.7% | 13.0% ▲18.2% | 11.0% ▲10.0% | 10.0% ▼41.2% | 17.0% ▲88.9% | 9.0% ▲12.5% | 8.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹108 Cr ▲0.0% | ₹108 Cr ▲0.0% | ₹108 Cr ▲0.0% | ₹108 Cr ▲0.9% | ₹107 Cr ▲0.0% | ₹107 Cr ▲0.0% | ₹107 Cr ▲0.9% | ₹106 Cr ▲0.0% | ₹106 Cr ▲0.0% | ₹106 Cr |
| Reserves | ₹4.7K Cr ▲7.6% | ₹4.4K Cr ▲9.0% | ₹4.0K Cr ▲1.9% | ₹3.9K Cr ▲21.1% | ₹3.2K Cr ▲30.3% | ₹2.5K Cr ▲49.7% | ₹1.7K Cr ▲14.5% | ₹1.5K Cr ▲5.4% | ₹1.4K Cr ▲12.4% | ₹1.2K Cr |
| Borrowings | ₹2.2K Cr ▼20.0% | ₹2.8K Cr ▲7.3% | ₹2.6K Cr ▲27.9% | ₹2.0K Cr ▲13.4% | ₹1.8K Cr ▲19.9% | ₹1.5K Cr ▲37.3% | ₹1.1K Cr ▲4.2% | ₹1.0K Cr ▲5.7% | ₹980 Cr ▲16.4% | ₹842 Cr |
| Other Liabilities | ₹2.4K Cr ▲14.2% | ₹2.1K Cr ▲23.5% | ₹1.7K Cr ▲5.7% | ₹1.6K Cr ▼12.6% | ₹1.8K Cr ▲10.1% | ₹1.7K Cr ▲85.5% | ₹901 Cr ▲22.3% | ₹737 Cr ▲33.0% | ₹554 Cr ▲15.2% | ₹481 Cr |
| Total Liabilities | ₹9.4K Cr ▲0.8% | ₹9.3K Cr ▲11.3% | ₹8.4K Cr ▲9.5% | ₹7.7K Cr ▲9.9% | ₹7.0K Cr ▲21.2% | ₹5.8K Cr ▲53.4% | ₹3.8K Cr ▲12.6% | ₹3.3K Cr ▲10.4% | ₹3.0K Cr ▲13.7% | ₹2.7K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹4.2K Cr ▲2.9% | ₹4.1K Cr ▲6.0% | ₹3.9K Cr ▲14.1% | ₹3.4K Cr ▲28.5% | ₹2.7K Cr ▲22.2% | ₹2.2K Cr ▲25.8% | ₹1.7K Cr ▲6.0% | ₹1.6K Cr ▲10.0% | ₹1.5K Cr ▲20.4% | ₹1.2K Cr |
| CWIP | ₹541 Cr ▲18.1% | ₹458 Cr ▲8.3% | ₹423 Cr ▼23.2% | ₹551 Cr ▼32.2% | ₹813 Cr ▲124.6% | ₹362 Cr ▲440.3% | ₹67 Cr ▼39.1% | ₹110 Cr ▼32.5% | ₹163 Cr ▲14.0% | ₹143 Cr |
| Investments | ₹261 Cr ▲12.0% | ₹233 Cr ▲87.9% | ₹124 Cr ▲148.0% | ₹50 Cr ▲61.3% | ₹31 Cr ▲933.3% | ₹3 Cr ▲0.0% | ₹3 Cr ▲0.0% | ₹3 Cr ▲0.0% | ₹3 Cr ▲0.0% | ₹3 Cr |
| Other Assets | ₹4.4K Cr ▼3.3% | ₹4.5K Cr ▲14.5% | ₹4.0K Cr ▲8.2% | ₹3.7K Cr ▲5.2% | ₹3.5K Cr ▲8.0% | ₹3.2K Cr ▲64.6% | ₹2.0K Cr ▲22.9% | ₹1.6K Cr ▲16.1% | ₹1.4K Cr ▲7.2% | ₹1.3K Cr |
| Total Assets | ₹9.4K Cr ▲0.8% | ₹9.3K Cr ▲11.3% | ₹8.4K Cr ▲9.5% | ₹7.7K Cr ▲9.9% | ₹7.0K Cr ▲21.2% | ₹5.8K Cr ▲53.4% | ₹3.8K Cr ▲12.6% | ₹3.3K Cr ▲10.4% | ₹3.0K Cr ▲13.7% | ₹2.7K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹602 Cr ▼9.6% | ₹666 Cr ▼33.0% | ₹994 Cr ▲9.1% | ₹911 Cr ▲24.3% | ₹733 Cr ▲111.2% | ₹347 Cr ▲16.4% | ₹298 Cr ▼12.9% | ₹342 Cr ▲3.0% | ₹332 Cr ▲82.4% | ₹182 Cr |
| Investing CF | ₹-680 Cr ▲17.3% | ₹-822 Cr ▲17.6% | ₹-997 Cr ▼9.1% | ₹-914 Cr ▲2.9% | ₹-941 Cr ▼325.8% | ₹-221 Cr ▲12.6% | ₹-253 Cr ▲34.1% | ₹-384 Cr ▼32.9% | ₹-289 Cr ▲7.4% | ₹-312 Cr |
| Financing CF | ₹39 Cr ▼84.4% | ₹250 Cr ▲1025.9% | ₹-27 Cr ▼190.0% | ₹30 Cr ▼88.2% | ₹255 Cr ▲299.2% | ₹-128 Cr ▼184.4% | ₹-45 Cr ▼207.1% | ₹42 Cr ▲177.8% | ₹-54 Cr ▼152.4% | ₹103 Cr |
| Net Cash Flow | ₹-39 Cr ▼141.9% | ₹93 Cr ▲410.0% | ₹-30 Cr ▼211.1% | ₹27 Cr ▼42.6% | ₹47 Cr ▲4800.0% | ₹-1 Cr | ₹0 Cr ▼100.0% | ₹1 Cr ▲110.0% | ₹-10 Cr ▲63.0% | ₹-27 Cr |
| Free Cash Flow | ₹61 Cr ▲710.0% | ₹-10 Cr ▼266.7% | ₹6 Cr ▼82.4% | ₹34 Cr ▼30.6% | ₹49 Cr ▼60.8% | ₹125 Cr ▲184.1% | ₹44 Cr ▲189.8% | ₹-49 Cr ▼189.1% | ₹55 Cr ▲138.2% | ₹-144 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132d ▲10.0% | 120d ▲25.0% | 96d ▼4.0% | 100d ▲1.0% | 99d ▼2.9% | 102d ▼9.7% | 113d ▲11.9% | 101d ▼7.3% | 109d ▲19.8% | 91d |
| Inventory Days | 285d ▲2.9% | 277d ▲24.8% | 222d ▼24.2% | 293d ▲10.2% | 266d ▲13.7% | 234d ▲16.4% | 201d ▲0.0% | 201d ▲8.1% | 186d ▲5.7% | 176d |
| Days Payable | 141d ▼10.8% | 158d ▲68.1% | 94d ▼35.6% | 146d ▼26.6% | 199d ▲25.2% | 159d ▲10.4% | 144d ▲34.6% | 107d ▲11.5% | 96d ▲6.7% | 90d |
| Cash Conv. Cycle | 276d ▲15.0% | 240d ▲7.1% | 224d ▼9.3% | 247d ▲48.8% | 166d ▼6.2% | 177d ▲4.1% | 170d ▼12.8% | 195d ▼2.0% | 199d ▲11.8% | 178d |
| Working Capital Days | 43d ▲2.4% | 42d ▼28.8% | 59d ▲37.2% | 43d ▲0.0% | 43d ▲186.7% | 15d ▲150.0% | 6d ▲154.5% | -11d ▼466.7% | 3d ▼84.2% | 19d |
| ROCE | 9.0% ▲28.6% | 7.0% ▼69.6% | 23.0% ▼11.5% | 26.0% ▼35.0% | 40.0% ▲185.7% | 14.0% ▲75.0% | 8.0% ▼42.9% | 14.0% ▼12.5% | 16.0% ▲0.0% | 16.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Laurus Labs Limited
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Laurus Labs Limited share price today?▾
Laurus Labs Limited (LAURUSLABS) is currently trading at ₹1,445.5 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Laurus Labs Limited available in F&O (Futures & Options)?▾
Yes, Laurus Labs Limited (LAURUSLABS) is part of the NSE F&O segment with a lot size of 850 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Laurus Labs Limited 52-week high and low?▾
Laurus Labs Limited's 52-week high is ₹1,399 and the 52-week low is ₹609. The current price of ₹1,445.5 is -3.3% below the 52W high.
What is Laurus Labs Limited P/E ratio?▾
Laurus Labs Limited's current P/E ratio is 84. This indicates the market is paying ₹84 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Laurus Labs Limited options?▾
Laurus Labs Limited options are traded on NSE with monthly expiry contracts (lot size: 850 shares). To trade LAURUSLABS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.